CONTINUOUS BIOPROCESSING – JUSTIFYING YOUR COMPANY’S INVEST



Continuous Bioprocessing – Justifying Your Company’s Investment Opening Remarks

The Continuous Learning Curve: Selecting the Right Products, Platforms, Equipment

Simon Hawdon (Principal Scientist, CPI’s National Biologics Manufacturing Centre) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss The Continuous Learning Curve: Selecting the Right Products, Platforms, and Equipment.

A Continuous Vision to the Future of Biomanfacturing

Chris Hwang (EVP, Chief Technical Officer, Transcenta Therapeutics) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss A Continuous Vision to the Future of Biomanufacturing.

Justifying the Continuous Investment

Andy Topping (VP Bioprocess and Product Development, FUJIFILM Diosynth Biotechnologies) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss Justifying the Continuous Investment.

NO SUMMARY ARTICLE

The Financial Impact of a Continuous Strategy

Joseph Shultz (VP Bioprocess and Product Development, Evelo Biosciences) and moderator John Bonham-Carter (Vice President Business Development and Product Management, Erbi Biosystems) discuss The Financial Impact of a Continuous Strategy.